Takeda's azilsartan approved in the US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Takeda's angiotensin II antagonist Edarbi (azilsartan medoxomil) for the treatment of hypertension in adults, for use either alone or in combination with other antihypertensives. The standard dose is 80mg once daily, although a starting dose of 40mg/day may be appropriate for patients on high doses of diuretics.